High Serum S100B Protein Levels As A Predictor Of Cognitive Function Disorders In Moderate Traumatic Brain Injury Patients

Abstract

Objective: To prove high serum S100B protein levels as a predictor of impaired cognitive function in patients with moderate traumatic brain injury. Method: A prospective cohort analytic observational study. The subjects are patients with a moderate degree of TBI with inclusion criteria: onset of TBI 24 hours, age 17-40 years old, and the exclusion criteria were the presence of impaired cognitive function pre-traumatic brain injury (Short IQCODE) 3), depression and multiple trauma. Patients/families/guardians who agreed to the informed consent were checked for S100B levels at <24 hours, then matched with the Montreal Cognitive Assessment version Indonesia (MoCA-INA) questionnaire on day 14 after TBI. This study’s data analysis consisted of univariate and bivariate analysis using Chi-Square. The significance level is stated with p <0.05, 95% confidence interval (CI) assisted by the IBM SPSS version 23. Results: There were 43 research subjects; 23 in the high S100B group and 20 in the S100B group were not high. The mean age is 28 years, with a ratio of 4:1 for men and females. Most of the years, education ≥12 years. The incidence of cognitive dysfunction in patients with moderate traumatic brain injury in the high serum S100B group was 76.19%, while in the non-high serum S100B group was 23.80%, with RR = 6.85, with 95% CI between 1.78-26 .36, and p-value = 0.005. Conclusion: High serum S100B protein levels as a predictor of cognitive function disorders were statistically significant in moderate traumatic brain injury patients with a risk of 6.85 times.